The earnings call for Verona Pharma plc reflected a positive sentiment overall, driven by the successful launch and strong sales of O2VERE, significant financial achievements, and robust progress in global regulatory and intellectual property strategies. Despite some financial losses and high expenses, the company's strong cash position and strategic financing provide a solid foundation for continued growth.

Company Guidance -

Q1 2025

In the first quarter of 2025, Verona Pharma plc reported significant progress in the launch of O2VERE, their new COPD treatment, with quarterly revenue surpassing operating expenses excluding noncash charges. O2VERE sales almost doubled compared to the previous quarter, reaching $71.3 million in net product sales. The company recorded a total net revenue of $76.3 million, buoyed by a $5 million milestone from Nuance Pharma. In terms of prescriptions, 25,000 were filled, new patient starts increased by over 25% compared to Q4 2024, and refills accounted for 60% of all expenses. The prescriber base grew by approximately 50%, with around 5,300 prescribers, 60% of whom are tier one healthcare providers. Financially, the company maintained a strong balance sheet with $401.4 million in cash and equivalents and an adjusted net income of $20.5 million, excluding $36.8 million in share-based compensation. Additionally, Verona Pharma amended its financing arrangement, increasing its debt facility to $450 million and repurchasing a $100 million obligation, enhancing financial flexibility.

Successful US Launch of O2VERE

O2VERE, the new COPD treatment, nearly doubled its sales from Q4 2024 to Q1 2025, reaching $71.3 million in net product sales. Prescriptions increased to approximately 25,000 filled during the first quarter, with a 25% growth in new patient starts compared to Q4 2024.

Financial Milestones

For the first time, Verona's quarterly revenue exceeded quarterly operating expenses excluding noncash charges. Adjusted net income for the quarter was $20.5 million, excluding $36.8 million in share-based compensation.

Strong Global Strategy and Regulatory Progress

O2VERE was approved in Macau for the treatment of COPD, marking the first regulatory approval outside the US. Nuance Pharma is expected to report results from its pivotal phase three trial for COPD treatment in China in Q2.

Expansion of Intellectual Property

A new Orange Book listed patent for O2VERE with an expiration date in 2044 was granted, bringing the total to four Orange Book listed patents.

Strong Financial Position

Verona ended Q1 2025 with $401.4 million in cash and equivalents, and amended its strategic financing arrangement for increased financial flexibility and reduced cost of capital.

Verona Pharma (VRNA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VRNA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 31, 2025	2025 (Q2)	<0.01 / -	-0.11	―	―	―
Apr 29, 2025	2025 (Q1)	-0.08 / -0.02	-0.04	50.00% (+0.02)	―
Feb 27, 2025	2024 (Q4)	-0.03 / -0.05	-0.02	-150.00% (-0.03)	―
Nov 04, 2024	2024 (Q3)	-0.07 / -0.07	-0.02	-250.00% (-0.05)	―
Aug 08, 2024	2024 (Q2)	-0.04 / -0.11	-0.01	-1000.00% (-0.10)	―
May 09, 2024	2024 (Q1)	-0.03 / -0.04	-0.03	-33.33% (-0.01)	―
Feb 29, 2024	2023 (Q4)	-0.03 / -0.02	-0.02	0.00% (0.00)	―
Nov 02, 2023	2023 (Q3)	-0.03 / -0.02	-0.03	33.33% (<+0.01)	―
Aug 03, 2023	2023 (Q2)	-0.03 / -0.01	-0.04	75.00% (+0.03)	―
May 09, 2023	2023 (Q1)	-0.08 / -0.03	-0.05	40.00% (+0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VRNA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 29, 2025	$68.83	$73.22	+6.38%
Feb 27, 2025	$63.52	$67.12	+5.67%
Nov 04, 2024	$34.98	$38.15	+9.06%
Aug 08, 2024	$19.53	$21.60	+10.60%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Verona Pharma Plc (VRNA) report earnings?

Verona Pharma Plc (VRNA) is schdueled to report earning on Jul 31, 2025, TBA (Confirmed).

What is Verona Pharma Plc (VRNA) earnings time?

Verona Pharma Plc (VRNA) earnings time is at Jul 31, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VRNA EPS forecast?

VRNA EPS forecast for the fiscal quarter 2025 (Q2) is <0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing